Soluble dipeptidyl peptidase-4 induces microvascular endothelial dysfunction through proteinase-activated receptor-2 and thromboxane A2 release

Journal of Hypertension

Volumn 34, Issue 5, 2016, Pages 869-876

  Romacho, Tania ^a   Vallejo, Susana ^b   Villalobos, Laura A ^b   Wronkowitz, Nina ^a   Indrakusuma, Ira ^a   Sell, Henrike ^a   Eckel, Juergen ^a   Sanchez Ferrer, Carlos F ^b   Peiro, Concepcion ^b  

^a LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Dipeptidyl peptidase 4 inhibitors; Endothelial dysfunction; Protease activated receptor 2; Soluble dipeptidyl peptidase 4; Thromboxane A2; Vascular reactivity

Indexed keywords

ACETYLCHOLINE; APOCYNIN; CELECOXIB; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; INDOMETACIN; LINAGLIPTIN; NORADRENALIN; PROSTAGLANDIN SYNTHASE; PROTEINASE ACTIVATED RECEPTOR 2; THROMBOXANE A2; THROMBOXANE RECEPTOR BLOCKING AGENT;

ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; CORONARY ARTERY ENDOTHELIAL CELL; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEISURE; MESENTERIC ARTERY; MOUSE; MUSCLE CONTRACTILITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION; VASCULAR SMOOTH MUSCLE; VASODILATATION; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; VASCULAR ENDOTHELIUM;

ANIMALS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; MESENTERIC ARTERIES; MICE; MICE, INBRED C57BL; RECEPTOR, PAR-2; THROMBOXANE A2;

EID: 84958793939     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000886     Document Type: Article

References (30)

1. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation 2007; 115:1285-1295
2. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev 2012; 33:187-215
3. Lamers D, Famulla S, Wronkowitz N, Hartwig S, Lehr S, Ouwens DM, et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 2011; 60:1917-1925
4. Dos Santos L, Salles TA, Arruda-Junior DF, Campos LC, Pereira AC, Barreto AL, et al. Circulating dipeptidyl peptidase IV activity correlates with cardiac dysfunction in human and experimental heart failure. Circ Heart Fail 2013; 6:1029-1038
5. Shah Z, Kampfrath T, Deiuliis JA, Zhing J, Pineda C, Ying Z, et al. Longterm dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 2011; 124:2338-2349
6. Fadini GP, Avogaro A. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vascul Pharmacol 2011; 55:10-16
7. Chrysant SG, Chrysant GS. Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors. Am J Cardiol 2012; 109:1681-1685
8. Patil HR, Al Badarin FJ, Al Shami HA, Bhatti SK, Lavie CJ, Bell DS, et al. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. Am J Cardiol 2012; 110:826-833
9. Nakamura K, Oe H, Kihara H, Shimada K, Fukuda S, Watanabe K, et al. DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study. Cardiovasc Diabetol 2014; 13:110
10. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 373:232-242
11. Ruiz-Hurtado G, Ruilope LM. Salutary cardiovascular effects of antidiabetic drugs: myth or fact? J Hypertens 2015; 33:2198-2199
12. Wronkowitz N, Gorgens SW, Romacho T, Villalobos LA, Sanchez-Ferrer CF, Peiro C, et al. Soluble DPP4 induces inflammation and proliferation of human smooth muscle cells via protease-activated receptor 2 (2014). Biochem Biophys Acta 2014; 1842:1613-1621
13. Rodriguez-Manas L, El-Assar M, Vallejo S, Lopez-Doriga P, Solis J, Petidier R, et al. Endothelial dysfunction in aged humans is related with oxidative stress and vascular inflammation. Aging Cell 2009; 8:226-238
14. Li H, Horke S, Fostermann U. Oxidative stress in vascular disease and its pharmacological intervention. Trends Pharmacol Sci 2013; 34:313-319
15. Feletou M, Huang Y, Vanhoutte P. Endothelium-mediated control of vascular tone: COX-1 and COX-2 products. Br J Pharmacol 2011; 164:894-912
16. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al., SAVOR-TIMI 53 Steering Committee and Investigators. SAVORTIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369:1317-1326
17. Jackson EK, Mi Z, Tofovic SP, Gillespie DG. Effect of dipeptidyl peptidase 4 inhibition on arterial blood pressure is context dependent. Hypertension 2015; 65:238-249
18. Fadini GP, Albiero M, Avogaro A. Direct effects of DPP-4 inhibition on the vasculature. Reconciling basic evidence with lack of clinical evidence. Vasc Pharmacol 2015; 73:1-3
19. Heise T, Graefe-Mody EU, Huttner S, Ring A, Trommeshauser D, Dugi KA. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab 2009; 11:786-794
20. Nystrom T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahren B, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004; 287:1209-1215
21. Green BD, Hand KV, Dougan JE, McDonnell BM, Cassidy RS, Grieve DJ. GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP. Arch Biochem Biophys 2008; 478:136-142
22. Zhong J, Rao X, Rajagopalan S. An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease. Atherosclerosis 2013; 226:305-314
23. Gieseler F, Ungefroren H, Settmacher U, Hollenberg MD, Kaufmann R. Proteinase-activated receptors (PARs): focus on receptor-receptorinteractions and their physiological and pathophysiological impact. Cell Commun Signal 2013; 11:86
24. Hung TT, Wu JY, Liu JF, Cheng HC. Epitope analysis of the rat dipeptidyl peptidase IV monoclonal antibody 6A3 that blocks pericellular fibronectin-mediated cancer cell adhesion. FEBS J 2009; 22:6548-6559
25. Li Y, Mihara K, Saifeddine M, Krawetz A, Lau DC, Li H, et al. Perivascular adipose tissue-derived relaxing factors: release by peptide agonists via proteinase-activated receptor-2 (PAR2) and non-PAR2 mechanisms. Br J Pharmacol 2011; 164:1990-2002
26. El-Daly M, Saifeddine M, Mihara K, Ramachandran R, Triggle CR, Hollenberg MD. Proteinase-activated receptors 1 and 2 and the regulation of porcine coronary artery contractility: a role for distinct tyrosine kinase pathways. Br J Pharmacol 2014; 171:2413-2425
27. Syeda F, Grosjean J, Houliston RA, Keogh RJ, Carter TD, Paleolog E, et al. Cyclooxygenase-2 induction and prostacyclin release by protease-activated receptors in endothelial cells require cooperation between mitogen-activated protein kinase and NF-kappaB pathways. J Biol Chem 2006; 281:11792-11804
28. van der Merwe JQ, Ohland CL, Hirota CL, MacNaughton WK. Prostaglandin E2 derived from cyclooxygenases 1 and 2 mediates intestinal epithelial ion transport stimulated by the activation of proteaseactivated receptor. J Pharmacol Exp Ther 2009; 32:747-752
29. Hirota CL, Moreau F, Iablokov V, Dicay M, Renaux B, Hollenberg MD, et al. Epidermal growth factor receptor transactivation is required for proteinase-activated receptor-2-induced COX-2 expression in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 2012; 303:111-119
30. Feletou M, Cohen RA, Vanhoutte PM, Verbeuren TJ. TP Receptors and oxidative stress: hand in hand from endothelial dysfunction to atherosclerosis. Adv Pharmacol 2010; 60:85-106